Related content

What did the 2009 H1N1 pandemic teach us about influenza surveillance systems?

By Stoto Michael A  

Future Virology, Vol. 8, Iss. 9, 2013-09 ,pp. : 829-832

Future Medicine

Access to resources Recommend Favorite

Oseltamivir in Seasonal, Avian H5N1 and Pandemic 2009 A/H1N1 Influenza: Pharmacokinetic and Pharmacodynamic Characteristics

By Widmer Nicolas  

Clinical Pharmacokinetics, Vol. 49, Iss. 11, 2010-11 ,pp. : 741-765

Adis International

Access to resources Recommend Favorite

While the adjuvanted monovalent 2009 H1N1 pandemic influenza vaccine [Arepanrix] contains residual egg protein, it appears to be safe in children with egg allergy

By  

Reactions Weekly, Vol. 1, Iss. 1315, 2010-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite

First French Experience of ADR Reporting by Patients After a Mass Immunization Campaign with Influenza A (H1N1) Pandemic Vaccines: A Comparison of Reports Submitted by Patients and Healthcare Professionals

By Durrieu Geneviève   Palmaro Aurore   Pourcel Laure   Caillet Céline   Faucher Angeline   Jacquet Alexis  

Drug Safety, Vol. 35, Iss. 10, 2012-10 ,pp. : 845-854

Adis International

Access to resources Recommend Favorite

Influenza A virus vaccine H1N1/influenza virus vaccine: Lack of efficacy in H1N1 influenza: case report

By  

Reactions Weekly, Vol. 1, Iss. 1421, 2012-01 ,pp. : 31-31

Adis International

Access to resources Recommend Favorite